Biopharmaceutical giant AstraZeneca has partnered with start-up “unicorn” Owkin to develop an AI-powered tool to prescreen for gBRCA mutations on the basis of morphological features in digitized pathology slides. Built on extensive, high-quality data sourced from the France-based PortrAIt consortium, the AI will help to prioritize patients for further testing, streamlining the diagnostic process, Owkin says.
"Unicorn" start-up Owkin and AstraZeneca are developing an AI-powered breast cancer prescreening solution under a partnership announced on 2 October.
According to French-American Owkin, which bills itself as “the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics,” the AI tool in development...